Scaling up antiretroviral therapy in South Africa: The impact of speed on survival

Journal of Infectious Diseases

Volumn 197, Issue 9, 2008, Pages 1324-1332

  Walensky, Rochelle P ^a,b,c   Wood, Robin ^h   Weinstein, Milton C ^d   Martinson, Neil A ^f,i   Losina, Elena ^b,c,e   Fofana, Mariam O ^a   Goldie, Sue J ^d   Divi, Nomita ^a   Yazdanpanah, Yazdan ^j,k,l   Wang, Bingxia ^a,c   Paltiel, A David ^g   Freedberg, Kenneth A ^a,c,d,e  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^f JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF CAPE TOWN   (South Africa)

ⁱ UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^j Service Universitaire des Maladies Infectieuses et du Voyageur   (France)

^k UNIV LILLE   (France)

^l CNRS   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ARTICLE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MORTALITY; PRIORITY JOURNAL; SIMULATION; SOUTH AFRICA; SURVIVAL RATE;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; HIV INFECTIONS; HUMANS; MODELS, BIOLOGICAL; SOUTH AFRICA;

EID: 43049100345     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/587184     Document Type: Article

References (39)

1. The Joint United Nations Programme on HIV/AIDS. 2006 Report on the global AIDS epidemic. 2006. Available at: http://www.unaids.org/en/HIV_data/ 2006GlobalReport/default.asp. Accessed 7 June 2007.
2. World Health Organization. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector. 2007. Available at: http://www.who.int/hiv/mediacentre/univeral_access_progress_report_en.pdf. Accessed 8 November 2007.
3. President's Emergency Plan for AIDS Relief. 2007 country profile: South Africa. 2007. Available at: http://www.pepfar.gov/documents/organization/ 81668.pdf. Accessed 13 November 2007.
4. The Global Fund to fight AIDS, TB, and Malaria: Partners in Impact results report 2007. Available at: http://www.theglobalfund.org/en/files/ about/replenishment/oslo/Progress%20Report.pdf. Accessed 7 June 2007.
5. Nattrass N. South Africa's "rollout" of highly active antiretroviral therapy: a critical assessment. J Acquir Immune Defic Syndr 2006; 43:618-23.
6. HIV and AIDS and STI strategic plan for South Africa, 2007-2011 (Draft 9). 2007. Available at: http://www.doh.gov.za/docs/misc/stratplan-f.html. Accessed 7 June 2007.
7. World Health Organization. Progress on global access to HIV antiretroviral therapy: a report on "3 by 5" and beyond. 2006. Available at: http://www.who.int/hiv/fullreport_en_highres.pdf. Accessed 7 June 2007.
8. Goldie SJ, Kuhn L, Denny L, Pollack A, Wright TC. Policy analysis of cervical cancer screening strategies in low-resource settings: clinical benefits and cost-effectiveness. JAMA 2001; 285:3107-15.
9. World Health Organization. Guidelines on co-trimoxazole prophylaxis for HIV-related infections among children, adolescents and adults. 2006. Available at: http://www.who.int/hiv/pub/guidelines/ctx/en/index.html. Accessed 7 June 2007.
10. Johnson M, Grinsztejn B, Rodriguez C. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failure with prior PI-containing regimen(s): 24-week results from BMS 043. AIDS 2005; 19:685-94.
11. Clotet B, Raffi F, Cooper D. Clinical management of treatment- experienced, HIV-infected patients with the fusion inhibitor enfuvirtide: consensus recommendations. AIDS 2004; 18:1137-46.
12. Harries AD, Schouten EJ, Libamba E. Scaling up antiretroviral treatment in resource-poor settings. Lancet 2006; 367:1870-2.
13. Goldie S, Yazdanpanah Y, Losina E, et al. Clinical benefits and cost-effectiveness of antiretroviral therapy for human immunodeficiency virus-infected patients in resource-poor settings: the case of Côte d'Ivoire. N Engl J Med 2006; 355:1141-53.
14. Yazdanpanah Y, Losina E, Anglaret X, et al. Clinical impact and cost-effectiveness of co-trimoxazole prophylaxis in patients with HIV/AIDS in Côte d'Ivoire: a trial-based analysis. AIDS 2005; 19:1299-308.
15. + lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997; 126:946-54.
16. Holmes CB, Wood R, Badri M, et al. CD4 decline and incidence of opportunistic infections in Cape Town, South Africa: implications for prophylaxis and treatment. J Acquir Immune Defic Syndr 2006; 42:464-9.
17. Akileswaran C, Lurie MN, Flanigan TP, Mayer KH. Lessons learned from use of highly active antiretroviral therapy in Africa. Clin Infect Dis 2005; 41:376-85.
18. Coetzee D, Hildrebrand K, Boulle A, et al. Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS 2004; 18:887-95.
19. Delfraissy J-F, Flandre P, Delaugerre C, et al. MONARK trial (monotherapy Antiretroviral Kaletra): 48-week analysis of lopinavir/ritonavir (LPV/r) monotherapy compared to LPV/r + zidovudine/Lamivudine (AZT/3TC) in antiretroviral-naive patients [abstract ThLB0202]. In: Program and abstracts of the XVI International AIDS Conference. Toronto, Canada, 2006.
20. Losina E, Yazdanpanah Y, Deuffic-Burban S, et al. The independent effect of highly active antiretroviral therapy on severe opportunistic disease incidence and mortality in HIV-infected adults in Côte d'Ivoire. Antivir Ther 2007; 12:543-51.
21. Badri M, Bekker L-G, Orrell C, Pitt J, Cilliers F, Wood R. Initiating highly active antiretroviral therapy in sub-Saharan Africa: an assessment of the revised World Health Organization scaling-up guidelines. AIDS 2004; 18:1159-68.
22. Lawn S, Badri M, Wood R. Tuberculosis among HIV-infected patients receiving HAART: long term incidence and risk factors in a South African cohort. AIDS 2005; 19:2109-16.
23. Badri M, Wilson D, Wood R. Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet 2002; 359:2059-64.
24. + lymphocyte count in African patients coinfected with HIV and tuberculosis. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 11:411-3.
25. Badri M, Wood R. Usefulness of total lymphocyte count in monitoring highly active antiretroviral therapy in resource-limited settings. AIDS 2003; 17:541-5.
26. World Health Organization. Scaling up antiretroviral treatment in resource-limited settings: treatment guidelines for a public health approach. 2003 revision. Available at: http://www.who.int/entity/hiv/pub/prev_care/ en/arvrevision2003en.pdf. Accessed 7 June 2007.
27. South Africa National Department of Health. National antiretroviral treatment guidelines. 2004. Available at: http://hivinsite.ucsf.edu/doc/ cr09-sf-01.doc. Accessed 7 June 2007.
28. Dorrington RE, Johnson L, Bradshaw D, T.-J. D. The demographic impact of HIV/AIDS in South Africa: national and provincial indicators for 2006. 2006. Available at: http://www.actuarialsociety.co.za/applications/cms/ documents/file_build.asp?id=100000148. Accessed 13 November 2007.
29. Morgan D, Mahe C, Mayanja B, Okongo JM, Lubega R, Whitworth JA. HIV-1 infection in rural Africa: is there a difference in median time to AIDS and survival compared with that in industrialized countries? AIDS 2002; 16:597-603.
30. Walensky RP, Goldie SJ, Sax PE, et al. Treatment for primary HIV infection: projecting outcomes of immediate, interrupted, or delayed therapy. J Acquir Immune Defic Syndr 2002; 31:27-37.
31. Actuarial Society of South Africa. ASSA 2003 summary statistics. 2003. Available at: http://www.actuarialsociety.co.za/applications/cms/ documents/file_build.asp?id=100000112. Accessed 9 November 2007.
32. Tutu D. New Congress can save lives, or money. Washington Post. January 15, 2007. Available at: http://www.washingtonpost.com/wp-dyn/ content/article/2007/01/13/AR2007011300496.html. Accessed 26 November 2007.
33. The other war. Wall Street Journal. December 29, 2006. Available at: http://www.malarianomore.org/media/mnm-wsj-122906.pdf. Accessed 26 November 2007.
34. Statistics South Africa. Mid-year population estimates, South Africa, 2006. Available at: http://www.statssa.gov.za/PublicationsHTML/P03022006/ html/P03022006.html. Accessed 7 June 2007.
35. World Health Organization. Summary country profile for HIV/AIDS treatment scale-up: South Africa. 2005. Available at: http://www.who.int/3by5/ support/june2005_zaf.pdf. Accessed June 7, 2007.
36. International HIV care, treatment, and prevention guidelines: South Africa. Available at: http://hivinsite.ucsf.edu/global?page=cr-00- 04#SsfguidelineX. Accessed 7 June 2007.
37. Malawi National AIDS Commission. Guidelines for the use of antiretroviral therapy in Malawi. 2003. Available at: http://www.aidsmalawi.org.mw/ resources/ARV%20GUILDELINES.pdf. Accessed 7 June 2007.
38. Full report of the Joint Health and Treasury Task Team charged with examining treatment options to supplement comprehensive care for HIV/AIDS in the public health sector. 2003. Available at: http://www.info.gov.za/ otherdocs/2003/treatment.pdf. Accessed 7 June 2007.
39. Gandhi NR, Moll A, Sturm AW, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006; 368:1575-80.